Kogulavadanan Arumaithurai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Kogulavadanan Arumaithurai has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Bradley F. Thompson
Department of Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN, USA
1 shared publication- Chelsey Hoffmann
Chelsey Hoffmann, PA-C, MS, RD, is a physician assistant, Division of Pain Medicine, Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota
1 shared publication - Deen Tar
College of Osteopathic Medicine, Touro University Nevada, Henderson, NV, USA
1 shared publication - Do Karen A. Truitt
Mayo Clinic Rochester, Minnesota, USA
1 shared publication - Do Nathan Young
Department of Neurology, Mayo Clinic, Rochester, MN
1 shared publication - Emad D. Singer
Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (1) , 100723
Associations between body mass index and patient reported biopsychosocial outcomes among patients with spine pain
- 17 December 2025
- Published by Elsevier in Interventional Pain Medicine
- Vol. 5 (1) , 100723
Open AccessAssociations between body mass index and patient reported biopsychosocial outcomes among patients with spine pain
- Open Access
- 18 January 2025
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (4) , 338-348
DEPDC5 mutations in familial epilepsy syndrome: genetic insights and therapeutic approaches
Background. DEPDC5 (disheveled, Egl-10 and pleckstrin domain-containing protein 5) familial epilepsy syndrome is a group of epilepsy disorders caused by mutations in DEPDC5 gene, which is a part of the gap activity towards rag 1 (GATOR1) complex involved in regulating the mechanism target of rapamycin (mTOR) pathway. These mutations lead to hyperactivation of the mTOR pathway, disrupting the shaping of neurons and resulting in increased excitatory transmission and the development of epilepsy. The incidence and prevalence of DEPDC5 familial epilepsy syndrome are not well established, but studies suggest it may account for up to 10% of familial focal epilepsy cases. Genetic testing, electroencephalography (EEG), and brain magnetic resonance imaging (MRI) are important in diagnosing the disorder, although normal MRI results are common.Objective: to explain the rare sporadic mutation in DEPDC5 gene with p.R389H, a variant of unknown significance.Case report. A 6-year-old South-Asian girl was born at 34-weeks from non-consanguineous marriage without any prenatal events. She had hyperbilirubinemia by week-1, which was successfully treated with phototherapy. Her initial seizure occurred when she was three months old, just 2 days after the fever from the vaccination had subsided. It was considered a simple-febrile seizure and no treatment was given. At 3.5-months, she started having recurrent seizures. Workup including MRI/ infectious/metabolic panel was non-conclusive. EEG during the initial presentation showed epileptiform activity from the left temporal region. Despite being on multiple anti-epileptic drugs, the child was diagnosed with refractory epilepsy. Subsequently, EEG at 2.5-years showed inter-ictal bi-hemispheric epileptiform activity. EEG at 5-years showed inter-ictal spikes and wave discharges from bilateral fronto-temporal region with secondary generalization. By 3-years, MRI showed mildly deformed corpus callosum with inadequate thickening of splenium. DNA analysis confirmed heterozygous missense mutation in exon 16 of DEPDC5 gene, without chromosomal abnormalities. Mother was heterozygous for the same mutation but no mutations in the father was found. The child has grossly delayed milestones. Corrected age is approximately 1-year for fine motor and language, 1.5-years for gross motor, 2.5-years for cognition, social skills. She had developed autistic features as well with significant impaired auditory/visual processing. She had hypotonia (Right>Left), wide-based gait, and extrapyramidal movements.Conclusion. DEPDC5 gene mutation results in amino acid substitution of Histidine for Arginine at codon 389. This mutation has shown to be inherited in familial pattern. This R389H variant is not present in the 1000 genomes database and is predicted to be benign. However, It rather appears to be a sporadic mutation, which is a very rarely observed phenomena. Such patients may respond well to mTOR inhibitors such as rapamycin, making prompt diagnosis and treatment crucial.
- 18 January 2025
- Published by IRBIS in Epilepsy and paroxysmal conditions
- Vol. 16 (4) , 338-348
Open AccessDEPDC5 mutations in familial epilepsy syndrome: genetic insights and therapeutic approaches
Background. DEPDC5 (disheveled, Egl-10 and pleckstrin domain-containing protein 5) familial epilepsy syndrome is a group of epilepsy disorders caused by mutations in DEPDC5 gene, which is a part of the gap activity towards rag 1 (GATOR1) complex involved in regulating the mechanism target of rapamycin (mTOR) pathway. These mutations lead to hyperactivation of the mTOR pathway, disrupting the shaping of neurons and resulting in increased excitatory transmission and the development of epilepsy. The incidence and prevalence of DEPDC5 familial epilepsy syndrome are not well established, but studies suggest it may account for up to 10% of familial focal epilepsy cases. Genetic testing, electroencephalography (EEG), and brain magnetic resonance imaging (MRI) are important in diagnosing the disorder, although normal MRI results are common.Objective: to explain the rare sporadic mutation in DEPDC5 gene with p.R389H, a variant of unknown significance.Case report. A 6-year-old South-Asian girl was born at 34-weeks from non-consanguineous marriage without any prenatal events. She had hyperbilirubinemia by week-1, which was successfully treated with phototherapy. Her initial seizure occurred when she was three months old, just 2 days after the fever from the vaccination had subsided. It was considered a simple-febrile seizure and no treatment was given. At 3.5-months, she started having recurrent seizures. Workup including MRI/ infectious/metabolic panel was non-conclusive. EEG during the initial presentation showed epileptiform activity from the left temporal region. Despite being on multiple anti-epileptic drugs, the child was diagnosed with refractory epilepsy. Subsequently, EEG at 2.5-years showed inter-ictal bi-hemispheric epileptiform activity. EEG at 5-years showed inter-ictal spikes and wave discharges from bilateral fronto-temporal region with secondary generalization. By 3-years, MRI showed mildly deformed corpus callosum with inadequate thickening of splenium. DNA analysis confirmed heterozygous missense mutation in exon 16 of DEPDC5 gene, without chromosomal abnormalities. Mother was heterozygous for the same mutation but no mutations in the father was found. The child has grossly delayed milestones. Corrected age is approximately 1-year for fine motor and language, 1.5-years for gross motor, 2.5-years for cognition, social skills. She had developed autistic features as well with significant impaired auditory/visual processing. She had hypotonia (Right>Left), wide-based gait, and extrapyramidal movements.Conclusion. DEPDC5 gene mutation results in amino acid substitution of Histidine for Arginine at codon 389. This mutation has shown to be inherited in familial pattern. This R389H variant is not present in the 1000 genomes database and is predicted to be benign. However, It rather appears to be a sporadic mutation, which is a very rarely observed phenomena. Such patients may respond well to mTOR inhibitors such as rapamycin, making prompt diagnosis and treatment crucial.
- Open Access
- 24 July 2023
- Published by Partners in Digital Health in Telehealth and Medicine Today
- Vol. 8 (4)
Patient Satisfaction and Perception of Physician Empathy in Outpatient Community General Neurology Telemedicine
Introduction: We assessed patients’ satisfaction and perception of physician empathy after implementation of video telemedicine service for general neurology follow-up visits at two community spoke clinics that serve patients in rural areas located approximately 45 miles from a medical center hub. Methods: Consecutive patients who completed a telemedicine neurology follow-up visit from February 12, 2020 to January 13, 2021 at the spoke clinic in Red Wing, MN and from July 21, 2021 to January 21, 2022 at the spoke clinic in Austin, MN were asked to complete a paper-based survey at the conclusion of the telemedicine visit. The neurologist conducted the telemedicine visit from the medical center hub site in Rochester, MN or from their own home using the InTouch (Teladoc Health™) operating system mobile telehealth platform. All patients had previously completed an initial traditional face-to-face consultation at the spoke clinic with the same neurologist performing the follow-up telemedicine visit. Primary outcomes were Telemedicine Patient Satisfaction Measure and Consultation and Relational Empathy scores and mean total favorable survey responses. Results: 31 patients at our clinic in Red Wing, MN and 38 patients at our clinic in Austin, MN participated in telemedicine neurology follow-up visit, completed the survey, and were included in the final analysis. The mean Telemedicine Patient Satisfaction Measure scores (possible score of 12-60) were 55 (range 42-60), and for all items ‘agree’ or ‘strongly agree’ was rated on average 94% of the time. The mean Consultation and Relational Empathy scores (possible score of 10–50) were 44 (range 28–50), and for all items ‘very good’ or ‘excellent’ was rated on average 90% of the time. Both neurologists conducting telemedicine visits reported that this model of care improved work-life balance with reduced travel time. Discussion: We successfully implemented a telemedicine service for general neurology follow-up visits at two community spoke clinics serving patients in rural areas without compromising on perceived care. We were able to bridge the gap between patients’ needs for local care and physicians’ need for work-life balance. Patients’ perception of physician empathy and satisfaction with telemedicine neurology follow-up visits was high. This model of telemedicine avoids the barriers of limited internet access in rural areas and minimizes technology related anxiety that is often present in telemedicine visits to patients’ homes. This model allowed for high quality neurological examination with high resolution pan-tilt-zoom camera on a mobile platform, incorporation of vital signs, nursing support, and lab services that may have contributed to the patients’ and neurologists’ satisfaction. Our study supports our continuation and expansion of this TM model in our community clinic spoke sites and may help to improve access to neurological care for patients in rural areas. Keywords: Telemedicine, patient satisfaction, empathy, general neurology, teleneurology
- 24 July 2023
- Published by Partners in Digital Health in Telehealth and Medicine Today
- Vol. 8 (4)
Open AccessPatient Satisfaction and Perception of Physician Empathy in Outpatient Community General Neurology Telemedicine
Introduction: We assessed patients’ satisfaction and perception of physician empathy after implementation of video telemedicine service for general neurology follow-up visits at two community spoke clinics that serve patients in rural areas located approximately 45 miles from a medical center hub. Methods: Consecutive patients who completed a telemedicine neurology follow-up visit from February 12, 2020 to January 13, 2021 at the spoke clinic in Red Wing, MN and from July 21, 2021 to January 21, 2022 at the spoke clinic in Austin, MN were asked to complete a paper-based survey at the conclusion of the telemedicine visit. The neurologist conducted the telemedicine visit from the medical center hub site in Rochester, MN or from their own home using the InTouch (Teladoc Health™) operating system mobile telehealth platform. All patients had previously completed an initial traditional face-to-face consultation at the spoke clinic with the same neurologist performing the follow-up telemedicine visit. Primary outcomes were Telemedicine Patient Satisfaction Measure and Consultation and Relational Empathy scores and mean total favorable survey responses. Results: 31 patients at our clinic in Red Wing, MN and 38 patients at our clinic in Austin, MN participated in telemedicine neurology follow-up visit, completed the survey, and were included in the final analysis. The mean Telemedicine Patient Satisfaction Measure scores (possible score of 12-60) were 55 (range 42-60), and for all items ‘agree’ or ‘strongly agree’ was rated on average 94% of the time. The mean Consultation and Relational Empathy scores (possible score of 10–50) were 44 (range 28–50), and for all items ‘very good’ or ‘excellent’ was rated on average 90% of the time. Both neurologists conducting telemedicine visits reported that this model of care improved work-life balance with reduced travel time. Discussion: We successfully implemented a telemedicine service for general neurology follow-up visits at two community spoke clinics serving patients in rural areas without compromising on perceived care. We were able to bridge the gap between patients’ needs for local care and physicians’ need for work-life balance. Patients’ perception of physician empathy and satisfaction with telemedicine neurology follow-up visits was high. This model of telemedicine avoids the barriers of limited internet access in rural areas and minimizes technology related anxiety that is often present in telemedicine visits to patients’ homes. This model allowed for high quality neurological examination with high resolution pan-tilt-zoom camera on a mobile platform, incorporation of vital signs, nursing support, and lab services that may have contributed to the patients’ and neurologists’ satisfaction. Our study supports our continuation and expansion of this TM model in our community clinic spoke sites and may help to improve access to neurological care for patients in rural areas. Keywords: Telemedicine, patient satisfaction, empathy, general neurology, teleneurology
- 28 September 2022
- Published by Taylor & Francis in Hospital Practice
- Vol. 50 (5) , 393-399
Cumulative rehospitalizations and implications for subsequent mortality after first-ever ischemic stroke
: Clinical implications of readmission following initial hospitalization for acute ischemic stroke (AIS) are not known. We examined predictors of readmissions and impact of readmissions on subsequent mortality after first-ever AIS. Adults aged ≥18 years who survived to discharge after hospitalization for first-ever AIS from 2003 to 2019 were included in the study. For each patient, the overall burden of hospitalizations was measured as total number of hospitalizations and aggregate days spent hospitalized during follow-up. We used Poisson regression to estimate incident rate ratios (IRR) for predictors of re-hospitalization and time-dependent Cox regression to estimate hazard ratios (HR) for mortality. Of 908 AIS survivors, 537 died, 669 had 2,645 readmissions for 4,535 person-years follow-up. Being white (IRR 1.21, 95% CI 1.03-1.42) dependency on discharge (IRR 1.27, 95% CI 1.17-1.38), cardio-embolism (IRR 1.35, 95% CI 1.18 – 1.45), smoking (IRR 1.21, 95% CI 1.08 – 1.35), anemia (IRR 1.40, 95% CI 1.24 – 1.57), arthritis (IRR 1.20, 95% CI 1.10 – 1.31), coronary artery disease (IRR 1.34, 95% CI 1.23 – 1.47), cancer (IRR 1.96, 95% CI 1.64 – 2.30), chronic kidney disease (IRR 1.36, 95% CI 1.21 – 1.57), COPD (IRR 1.18, 95% CI 1.04 – 1.34), depression (IRR 1.50, 95% CI 1.37 – 1.66), diabetes mellitus (IRR 1.48, 95% CI 1.36 – 1.48), and heart failure (IRR 1.17, 95% CI 1.03 – 1.34) were all independently associated with higher risk while hyperlipidemia (IRR 0.79, 95% CI 0.71 – 0.88) was associated with a lower risk of readmissions. Mortality was significantly increased with each hospitalization and cumulative days spent in hospital. Among survivors of AIS hospitalization, certain socio-demographic indicators, stroke-specific features, and several key comorbid conditions were associated with increased risk of readmissions which in turn correlated with increased mortality. Therefore, lifestyle modification and optimal treatment of comorbidities likely to improve the outcome after AIS.
- 28 September 2022
- Published by Taylor & Francis in Hospital Practice
- Vol. 50 (5) , 393-399
Cumulative rehospitalizations and implications for subsequent mortality after first-ever ischemic stroke
: Clinical implications of readmission following initial hospitalization for acute ischemic stroke (AIS) are not known. We examined predictors of readmissions and impact of readmissions on subsequent mortality after first-ever AIS. Adults aged ≥18 years who survived to discharge after hospitalization for first-ever AIS from 2003 to 2019 were included in the study. For each patient, the overall burden of hospitalizations was measured as total number of hospitalizations and aggregate days spent hospitalized during follow-up. We used Poisson regression to estimate incident rate ratios (IRR) for predictors of re-hospitalization and time-dependent Cox regression to estimate hazard ratios (HR) for mortality. Of 908 AIS survivors, 537 died, 669 had 2,645 readmissions for 4,535 person-years follow-up. Being white (IRR 1.21, 95% CI 1.03-1.42) dependency on discharge (IRR 1.27, 95% CI 1.17-1.38), cardio-embolism (IRR 1.35, 95% CI 1.18 – 1.45), smoking (IRR 1.21, 95% CI 1.08 – 1.35), anemia (IRR 1.40, 95% CI 1.24 – 1.57), arthritis (IRR 1.20, 95% CI 1.10 – 1.31), coronary artery disease (IRR 1.34, 95% CI 1.23 – 1.47), cancer (IRR 1.96, 95% CI 1.64 – 2.30), chronic kidney disease (IRR 1.36, 95% CI 1.21 – 1.57), COPD (IRR 1.18, 95% CI 1.04 – 1.34), depression (IRR 1.50, 95% CI 1.37 – 1.66), diabetes mellitus (IRR 1.48, 95% CI 1.36 – 1.48), and heart failure (IRR 1.17, 95% CI 1.03 – 1.34) were all independently associated with higher risk while hyperlipidemia (IRR 0.79, 95% CI 0.71 – 0.88) was associated with a lower risk of readmissions. Mortality was significantly increased with each hospitalization and cumulative days spent in hospital. Among survivors of AIS hospitalization, certain socio-demographic indicators, stroke-specific features, and several key comorbid conditions were associated with increased risk of readmissions which in turn correlated with increased mortality. Therefore, lifestyle modification and optimal treatment of comorbidities likely to improve the outcome after AIS.
- 1 April 2012
- Published by Wolters Kluwer Health
- Vol. 72 (4) , 1123
The case for brain death determination by CTA
- 1 April 2012
- Published by Wolters Kluwer Health
- Vol. 72 (4) , 1123
The case for brain death determination by CTA